Format

Send to

Choose Destination
J Biomed Biotechnol. 2010;2010:956304. doi: 10.1155/2010/956304. Epub 2010 May 5.

Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Author information

1
Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.

Abstract

CD4+ and CD8+ T lymphocytes are powerful components of adaptive immunity, which essentially contribute to the elimination of tumors. Due to their cytotoxic capacity, T cells emerged as attractive candidates for specific immunotherapy of cancer. A promising approach is the genetic modification of T cells with chimeric antigen receptors (CARs). First generation CARs consist of a binding moiety specifically recognizing a tumor cell surface antigen and a lymphocyte activating signaling chain. The CAR-mediated recognition induces cytokine production and tumor-directed cytotoxicity of T cells. Second and third generation CARs include signal sequences from various costimulatory molecules resulting in enhanced T-cell persistence and sustained antitumor reaction. Clinical trials revealed that the adoptive transfer of T cells engineered with first generation CARs represents a feasible concept for the induction of clinical responses in some tumor patients. However, further improvement is required, which may be achieved by second or third generation CAR-engrafted T cells.

PMID:
20467460
PMCID:
PMC2864912
DOI:
10.1155/2010/956304
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center